Silence Therapeutics

Activities: Research & Development

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Ingredients

AstraZeneca joins forces with Silence to develop siRNA therapeutics

Collaboration with Silence Therapeutics has been agreed to develop small interfering RNA therapeutics that act inside the cell to influence protein production

New CEO at Silence Therapeutics
Recruitment

Silence Therapeutics announces leadership change
Recruitment

Appointment of Dr Annalisa Jenkins as non-executive Chair
Regulatory

Silence strengthens US patent estate

Silence Therapeutics, developers of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced a further key US patent 9,695,423 has been granted to Silence this month
Pharmaceutical

Silence Therapeutics names Chief Operating Officer
Recruitment

Silence Therapeutics appoints Dmitry Samarsky as Chief Scientific Officer and Dr Andy Richards as Non-Executive Director

Silence's technology harnesses the body’s natural mechanisms to create therapeutic effects within its cells
Subscribe now